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Abstract 
Objectives The role of β-blockers in the treatment of hypertension is discussed 
controversially and the data showing a clear benefit in acute coronary syndromes 
(ACS) were obtained in the thrombolysis era. The goal of this study was to analyze 
the role of pretreatment with β-blockers in patients with ACS. 
 
Methods Using data from the Acute Myocardial Infarction in Switzerland (AMIS 
Plus) Registry, we analyzed outcomes of patients with β-blocker pretreatment in 
whom they were continued during hospitalization (group A), those without β-blocker 
pretreatment but with administration after admission (group B) and those who never 
received them (group C). Major adverse cardiac events (MACE) defined as composed 
endpoint of re-infarction and stroke (during hospitalization) and/or in-hospital death 
were compared between the groups. 
 
Results A total of 24709 patients were included in the study (n=6234 group A, 
n=12344 group B, n=6131 group C). Patients of group B were younger compared to 
patients of group A and C (62.5 vs. 67.6 vs. 68.4). In the multivariate analysis Odds 
Ratio for MACE was 0.59 (CI 0.4.7-0.74) for group A and 0.66 (CI 0.55-0.83) for 
group B while group C was taken as a reference.  
 
Conclusions β-blocker therapy is beneficial in ACS and they should be started in 
those who are not pre-treated and continued in stable patients who were on chronic β-
blocker therapy before.  
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Introduction 
 
While the role of beta-receptor blocking agents (β-blockers) has been challenged 
recently as a first choice in the treatment of systemic hypertension [1,2], β-blockers 
remain recommended medications for patients with chronic coronary artery disease 
[3], especially those after acute myocardial infarction (AMI) [4-6].  
 
In 1999 Freemantle and colleagues assessed the role of β-blockers in a large meta-
analysis of 54 234 patients with myocardial infarction [7]. They found that β-blockers 
are effective in the long term secondary prevention after myocardial infarction, 
reporting a 23 % reduction in the odds of death in long term trials (95 % confidence 
interval 15 to 31 %). Similar long-term results were reported by the β-blocker pooling 
research group [8] and the Cooperative Cardiovascular Project [9].   
 
The impact of β-blocker treatment on early outcomes after myocardial infarction has 
been discussed controversially. Freemantle et al. did not observe a positive short-term 
effect of β-blockers administered immediately after AMI (4% reduction in the odds of 
death; - 8 to 15%) [7].  
Also, the role of early intravenous β-blocker therapy has been disputed. While early 
studies performed in patients without reperfusion therapy demonstrated a mortality 
benefit [10,11], studies in the thrombolysis era showed no survival benefit [12,13] or 
even an increased mortality [14]. However, in the study by Pfisterer et al atenolol was 
used, a β-blocker which has been widely criticized lately, especially in hypertension 
trials [2]. 
Administration of intravenous β-blockers before primary percutaneous coronary 
intervention (PCI) was found to enhance myocardial recovery and reduce 30-day 
mortality in patients with AMI undergoing primary PCI [15]. A pooled analysis of 
three prospective trials showed that pretreatment with beta-blockers has an 
independent beneficial effect on short-term clinical outcomes in patients undergoing 
primary angioplasty for acute myocardial infarction [16]. In the most recent study, 
which analyzed the role of β-blockers in the treatment of AMI, 45000 patients were 
randomized to intravenous (continued with oral) metoprolol therapy or placebo. The 
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rate of death, re-infarction or cardiac arrest was similar between both groups in this 
study [17].  
One of the mechanisms how β-blockers could potentially improve prognosis in ACS 
is heart-rate reduction [18,19]. However, the concept of sole heart-rate reduction is 
discussed controversially after the publication of the BEAUTIFUL trial, which failed 
to reduce cardiovascular mortality in stable patients with CAD and reduced LV 
function, although reducing the rates of fatal and non-fatal myocardial infarction in 
these patients [20].  
Since the short-term effect of early administration of β-blockers in patients with 
unstable angina or AMI remains controversial and little is known about the early 
outcome of AMI patients already treated with β-blockers, there is need for further 
investigation.  
Using data from the Acute Myocardial Infarction in Switzerland (AMIS Plus), a large 
national registry of ACS, we have analysed the effect of previous β-blocker therapy 
on the outcome of patients with ACS. Our hypothesis was that in patients with ACS, 
previous β-blocker therapy does not offer additional benefit to a β-blocker therapy 
started after admission.  
 
Methods 
The AMIS Plus Registry 
The AMIS Plus project is a nationwide prospective registry of patients admitted with 
ACS to hospitals in Switzerland. The registry began in 1997, and patient recruitment 
has been ongoing since. Participating centres, ranging from community institutions to 
large tertiary facilities, provide blinded data for each patient through a standardised 
Internet- or paper-based questionnaire. The details of the AMIS Plus Project have 
been published elsewhere [21-24]. 
Patients 
The AMIS Plus registry included all patients with ACS: acute myocardial infarction defined by 
characteristic symptoms and/or ECG changes and cardiac marker elevation (either  total creatine kinase 
or creatine kinase MB fraction at least twice the upper limit of normal or troponin I or T above 
individual hospital cut-off for MI),  ACS with minimal necrosis (symptoms or ECG changes 
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compatible with ACS and cardiac marker  level lower than cut-off for MI) and unstable angina 
(symptoms or ECG changes compatible with ACS and normal cardiac markers). Patients were also 
categorized as having ST-segment elevation ACS (STEMI) or Non- ST-segment elevation ACS 
(NSTEMI) based on initial ECG findings. Classification of STEMI included evidence of ACS as above 
and ST-segment elevation and/or new left bundle branch block on the initial ECG. NSTEMI included 
patients with ischemic symptoms, ST-segment depression or T-wave abnormalities in the absence of 
ST-elevation on the initial ECG. Valid data since 1997 on pre-treatment and early treatment with β-
blockers were available and those data were analysed. Baseline characteristics and outcomes are 
compared between patients on chronic β-blocker therapy (group A), patients without β-blocker pre-
treatment and in whom β-blocker therapy was started after admission (group B), and patients without 
β-blocker pre-treatment who were not started on a β-blocker when admitted (group C). MACE was 
defined as a composed endpoint of re-infarction, stroke and/or in-hospital death. Comorbidities of the 
patients were assessed using the Charlson Index [25]. In March 2005 the AMIS Plus Questionnaire 
was revised and more angiographic parameters were added (e.g: vessel treated, left ventricular ejection 
fraction, thrombolysis in myocardial infarction (TIMI) flow at the end of percutaneous intervention 
(PCI)). 
Statistical Analyses 
Data are presented as percentages of valid cases for discrete variables and as mean + SD and / or 
median for continuous variables. Differences in baseline characteristics were compared using t-test and 
Chi-Square tests. A p value of < 0.05 was considered significant. User-defined missing values are 
treated as missing. Statistics for each table are based on all cases with valid data in the specified ranges 
for all variables in each table. Odds ratios (OR) with 95% of confidence interval for OR of in-hospital 
mortality were calculated using logistic regression models. The following factors were included in the 
multivariate analysis: β-blocker treatment, age, gender, history of coronary artery disease, 
hypertension, diabetes, dyslipidemia, smoking, overweight, ST-segment elevation, Charlson score, 
Killip class and use of PCI.  SPSS software (Chicago, Illinois; Version 15.0) was used for all statistical 
analyses.  
Results 
From 26,964 registered patients between January 1st 1997 to December 31st 2007, 
24,709 patients (97 %) had valid data on previous and/or early treatment with β-
blockers. For 2255 patients (8.4 %), treatment with β-blockers was unknown or data 
were missing. 
7684 patients (29.4 %) had previous β-blocker therapy and in 6234 of these patients 
this therapy was continued after admission (group A; in 1450 patients β-blockers were 
stopped after admission); in 12344 (47.2 %) patients β-blocker therapy was started at 
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admission (group B); 6131 (23.4 %) patients never received β-blocker therapy (group 
C). Baseline characteristics of the study population are shown in Table 1. The mean 
age of all patients was 65.6 years (+13.2) and 72.3 % of them were males. Patients of 
group A were significantly older than patients of group B (67.6 vs. 62.5 years, 
p<0.001) but had a similar age as patients of group C (68.4 years). 
Patients of group A had a higher proportion of diabetes (24.3 % vs. 15.8 % in group B 
and 22 % in group C, p<0.001) and a higher proportion of arterial hypertension (79.9 
% vs. 45.2% in group B and 50.4 % in group C).  
The rate of STEMI was higher in patients of group B and C (62.4 and 62.8 %) 
compared to patients of group A (47.6%, p< 0.001).  
The anti-thrombotic therapy is shown in the bottom part of table 1. Patients from 
group C received less aspirin and less clopidogrel than those of group A and B. 
 
In table 2 the Killip classifications of the patients are summarized. Patients of group B 
were more likely to be in Killip Class I (84.5 %) compared to patients of group A (77 
%) and patients of group C (66.1 %).  
Table 3 summarizes the reperfusion therapies for ACS patients in the AMIS Plus 
population. A reperfusion therapy (thrombolysis or primary PCI) was performed in 
45.8 % of patients of group A, 55.9 % of patients of group B and 48 % of patients of 
group C.  Primary PCI was the predominant reperfusion therapy in all groups.   
Median door-to-balloon times for PCI treated patients were 193 minutes for group A, 
117 minutes for group B and 109 minutes for group C (p<0.001). Median door-to-
needle time for Thrombolysis treated patients was 35 minutes in group A and 30 
minutes in group B and C (p=0.032). 
 
In Table 4 the complications and outcome of ACS patients during hospitalization are 
demonstrated. Patients of group B had similar rates or cardiogenic shock (3.8% vs. 
3.7 % in group A) but lower rates than group C (13.8% p<0.001). Re-infarction rates 
were 2.5 % in group A, 1.9 % in group B and 2.8 % in group C.   
 
Unadjusted MACE rates were similar in patients with β-blocker therapy on admission 
(group B) compared to those with previous β-blocker therapy (group A) (5.1 vs. 6.5 
%) but lower than those who never received β-blockers (group C, 15.5 %). 
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The unadjusted in-hospital mortality was 4.1 % for group A, 3.2 % for group B and 
13.2 % for group C.  
In Table 5 a multivariate logistic regression for major adverse cardiac events is 
shown. Factors increasing the MACE odds ratio are age, STEMI, a higher Killip 
Class, the history of CAD, diabetes and an increasing Charlson score. The odds ratio 
for β-blocker therapy on admission (group B) was 0.59, while the odds ratio for 
previous β-blocker therapy (group A) was 0.66.  
 
Discussion  
We analyzed a large population of patients with ACS who are prospectively registered 
in the AMIS Plus database. The majority of the patients (71 %) with ACS in 
Switzerland receive β-blocker therapy (either pre-treated and continued or started 
during hospitalization). The proportion of β-blockers use in our population is slightly 
lower compared to the proportion reported in the Worcester Heart Attack Study where 
in 1999, 82 % of the patients received this therapy after AMI [26].   
The unadjusted MACE and in-hospital mortality rate were slightly better in patients 
with β-blocker therapy started after admission, compared to those who had a chronic 
β-blocker therapy or those who never received a β-blocker (Table 4). However, it’s 
important to recognize the fact that there were significant differences between the 
different β-blocker groups (Table 1). One of the most important factors was age. 
Patients with previous β-blocker therapy and those who never received a β-blocker 
were more than 5 years older than patients with β-blocker therapy started after 
admission. It is well known that age increases the risk for adverse outcomes after non-
invasive and invasive therapies for acute myocardial infarction [27,28]. One of the 
reasons for this phenomenon is probably the lower of use of guideline-recommended 
medical and interventional therapies in elderly patients [23]. Increased percutaneous 
coronary intervention rates have been associated with decreased mortality among 
patients with ACS who present with cardiogenic shock or STEMI in Switzerland [29] 
[30].  
Further factors possibly explaining higher MACE rates are the higher prevalence of 
diabetes and coronary artery disease in patients pre-treated with β-blocking agents 
than those without a β-blocker therapy. A factor favouring a worse outcome in 
patients with β-blocker therapy after admission is the higher proportion of STEMI in 
  
8 
8 
this group (62.4 % vs. 47.6 % in patients with previous β-blocker therapy).  
 
Since the baseline characteristics of the groups were different, we performed a 
multivariate logistic regression analysis, which included the Charlson comorbidity 
score and is shown in Table 5. According to this analysis, both, previous β-blocker 
therapy and β-blocker therapy after admission are beneficial in patients with ACS. 
This multivariate analysis favours pre-treatment with β-blockers indicating a 41 % 
reduction of odds ratio with a 95 % CI 0.47-0.74.  
What could be the impact of these results when dealing with patients who present 
with ACS?  
Patients with β-blocker pre-treatment in whom this therapy is continued after 
admission do at least as good (or even better) than patients without pretreatment, in 
whom β-blockers are started after admission.  In 1045 of 7684 patients (13.6 %) with 
previous β-blockers, this therapy was stopped after admission. Despite the fact that 
we do not know the exact reasons why clinicians stopped β-blockers, we can assume 
that this was for hemodynamic reasons.  
The latest large prospective trial analyzing the role of β-blockers in AMI found that 
they reduce the risk of re-infarction and ventricular fibrillation but increase the risk of 
cardiogenic shock, especially during the first day after admission [17].  
When cautiously interpreted, our data call for a tailored approach. Patients who are 
pre-treated with β-blockers and who present with ACS should further receive their β-
blocker if they are hemodynamically stable since this medication has the potential to 
decrease their MACE rate to as much as 41 %. Patients without β-blocker 
pretreatment who are hemodynamically stable should receive this therapy soon after 
presentation for ACS.  
In our study, patients who never received a β-blocker therapy had very high rates of 
MACE. This is explained by their co-morbidities (age, diabetes, prevalence of known 
CAD, lower use of aspirin and clopidogrel) but might also be related to the fact that 
they never received β-blockers (a proven beneficial therapy for ACS).  
 
Limitations 
We are aware that these are registry data, which should be interpreted with caution. 
Since the baseline characteristics of the different β-blocker groups were so different, a 
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comparison of the outcomes is difficult and remains challenging despite the use of 
multivariate logistic regression.  
Additionally, we cannot provide data which types of β-blockers and in which dose 
they were used.  
Global data about baseline ejection fraction are not available for most of the patients 
and this limits the interpretations of the data since ejection fraction affects patient’s 
response to treatment with β-blockers. 
  
Conclusions 
This study confirms the potential benefit of β-blockers in patients with ACS. β-
blockers have the potential to markedly reduce in-hospital mortality and MACE rates 
in ACS patients. Hemodynamically stable patients without β-blocker pretreatment 
should receive them upon admission and this therapy should be continued in those 
already on β-blockers. 
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Appendix - AMIS Plus Participants 1997 – 2007   
The following hospitals participated from 1997-2007 in the AMIS registry on which 
this report is based (in alphabetical order): Affoltern am Albis, Bezirkspital (F Hess), 
Altdorf, Kantonsspital (R Simon), Altstätten, Kantonales Spital (PJ Hangartner / M 
Rhyner), Aarau, Kantonsspital (P Lessing), Baden, Kantonsspital (M Neuhaus/ U 
Hufschmid), Basel, Kantonsspital (P Hunziker), Basel, St. Claraspital (C Grädel), 
Bern, Beau-Site Klinik (A Schönfelder), Bern, Inselspital (B Meier / S Windecker), 
Biel, Spitalzentrum (H Schläpfer), Brig-Glis, Oberwalliser Kreisspital (D Evéquoz), 
Bülach, Spital (R Pampaluchi / A Ciurea-Löchel / M Kruhl/ A Vögele), Burgdorf, 
Regionalspital Emmental (D Ryser), Chur, Rätisches Kantons- und Regionalspital (P 
Müller), Chur, Kreuzspital (V Wüscher / R Jecker), Davos, Spital (G Niedermaier), 
Dornach, Spital (A Koelz / H Lederer), Flawil, Kantonales Spital (T Langenegger/J 
Haarer), Frauenfeld, Kantonsspital (HP Schmid), Fribourg, Hôpital cantonal (B 
Quartenoud),  Frutigen, Spital (S Moser / K Bietenhard), Genève, Hôpitaux 
universitaires (HUG) (JM Gaspoz/ PF Keller), Glarus, Kantonsspital (W. Wojtyna), 
Grenchen, Spital (P Schlup / A Oestmann / B Oertli / R Schönenberger), 
Grosshöchstetten, Bezirksspital (C Simonin), Heiden, Kantonales Spital (R 
Waldburger), Herisau, Kantonales Spital (P Staub / M Schmidli), Interlaken, Spital (P 
Sula/ EM Weiss), Jegenstorf, Spital (H Marty), La Chaux-de-Fonds, Hôpital (H 
Zender), Lachen, Regionalsspital (I Poepping / C Steffen), Langnau im Emmental, 
Regionalspital (J Sollberger / A Hugi), Laufenburg, Gesundheitszentrum Fricktal (E 
Koltai), Lugano, Cardiocentro Ticino (G Pedrazzini), Luzern, Kantonsspital (P Erne),  
Männedorf, Kreisspital (J von Meyenburg / T Luterbacher), Martigny, Hôpital 
régional (B Jordan), Mendrisio, Ospedale regionale (A Pagnamenta), Meyrin, Hôpital 
de la Tour (P Urban), Monthey, Hôpital du Chablais (P Feraud), Montreux, Hôpital de 
Zone (E Beretta), Moutier, Hôpital du Jura bernois (C Stettler), Münsingen, 
Regionales Spital Zentrum (F Repond), Münsterlingen, Kantonsspital (F Widmer), 
Muri, Kreisspital für das Freiamt (A Spillmann / F Scheibe / K Rudaz-Schwaller), 
Nyon, Group. Hosp. Ouest lémanique (R Polikar), Olten, Kantonsspital (S Bassetti), 
Rheinfelden, Gesundheitszentrum Fricktal (HU Iselin), Rorschach, Kantonales Spital 
(M Pfister / A Fischer), Samedan, Spital Oberengadin (P Egger), Sarnen, 
Kantonsspital Obwalden (T. Kaeslin), Schaffhausen, Kantonsspital (R. Frey), 
Schlieren, Spital Limmattal (B Risti / V Stojanovic / T Herren), Schwyz, Spital (P 
Eichhorn), Scuol, Ospidal d’Engiadina Bassa (G Flury / C Neumeier), Solothurn, 
Bürgerspital Solothurn (P Hilti / A Grât/ R. Schöneneberger), St. Gallen, 
Kantonsspital (W Angehrn / H Rickli), Sursee, Spital (S Yoon), Tiefenau, 
Tiefenauspital (P Loretan), Thun, Spital (U Stoller), Thusis, Krankenhaus (UP 
Veragut), Uster, Spital (D Maurer / J Muntwyler / J Hellermann), Uznach, Kantonales 
Spital (A Weber), Wädenswil, Schwerpunktspital Zimmerberg-Horgen (G Garzoli / B 
Kälin), Walenstadt, Kantonales Spital (H Matter / D Schiesser), Wetzikon, GZO 
Spital (M Graber), Winterthur, Kantonsspital (A Haller), Wolhlusen, Kantonales 
Spital (M Peter), Zofingen, Spital (HJ Vonesch / HJ Meier / S Gasser), Zollikerberg, 
Spital (P Siegrist / R Fatio), Zug, Kantonsspital (M Vogt / D Ramsay), Zürich, Klinik 
im Park (O Bertel), Zürich, Universitätsspital Zürich (F Eberli / M Maggiorini), 
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Zürich, Stadtspital Triemli (O Bertel / F Eberli), Zürich, Stadtspital Waid (M Brabetz 
/ S Christen). 
 
 
Tables  
 
Table 1  
Baseline characteristics of the study population 
 
 
 All ACS patients ACS patients with valid data on beta 
receptor blocking agents (BB) 
(N=26159) 
 
  
n=26964 
Group A 
Previous and 
continued BB 
(n=6234) 
Group B 
BB on 
admission 
(n=12344) 
Group C 
Never BB 
 
(n=6131) 
P 
Between 
groups 
Age, mean (SD) 65.6 (13.2) 67.6 (12.0) 62.5 (13.1) 68.4 (13.6) <0.001 
Male patients (%) 72.3 70.9  75.5 69.0 <0.001 
STEMI (n/N (%)) 15807/26881 
(58.8) 
2961/6216 
(47.6) 
7696/12326 
(62.4) 
3835/6108 
(62.8) 
<0.001 
CAD (n/N (%)) 8692/22226 
(39.1) 
3520/5575 
(63.1) 
2534/10025 
(25.3) 
1676/4793 
(35.0) 
<0.001 
Diabetes (n/N (%)) 5207/26045 
(20.0) 
1483/6094 
(24.3) 
1893/12002 
(15.8) 
1302/5911 
(22.0) 
<0.001 
Hypertension (n/N (%)) 14717/25794 
(57.1) 
4877/6105 
(79.9) 
5350/11833 
(45.2) 
2927/5809 
(50.4) 
<0.001 
Dyslipidemia (n/N (%)) 13800/24136 
(57.2) 
4024/5764 
(69.8) 
6109/11272 
(54.2) 
2516/5233 
(48.1) 
<0.001 
Smoking (n/N (%)) 9616/25356 
(37.9) 
1658/5891 
(28.1) 
5247/11916 
(44.0) 
2093/5622 
(37.2) 
<0.001 
Obesity (n/N (%)) 4110/21470 
(19.1) 
1142/5204 
(21.9) 
1847/10155 
(18.2) 
795/4464 
(17.8) 
<0.001 
  
 Aspirin 
5913/6229 
(94.9) 
12024/12333 
(97.5) 
5482/6122 
(89.5) 
<0.001 
  
 Clopidogrel 
3353/6206 
(54.0) 
6632/12298 
(53.9) 
2591/6116 
(42.4) 
<0.001 
  
UFH 
3989/6197 
(64.4) 
9080/12305 
(73.8) 
4288/6117 
(70.1) 
<0.001 
  
 LMWH 
1941/5333 
(36.4) 
3578/9755 
(36.7) 
1264/4577 
(27.6) 
<0.001 
Anti-Thrombotic 
Therapy 
 
 
 GP IIb/IIIa 
1544/5347 
(28.9) 
3716/9779 
(38.0) 
1341/4579 
(29.3) 
<0.001 
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Table 2 
Killip Classification 
 
 All ACS 
patients 
ACS patients with valid data on beta 
receptor blocking agents (BB) 
(N=26’159) 
 
  
n=26,964 
Group A 
 
Previous and 
continued BB 
(n=6234) 
Group B 
 
BB on 
admission 
(n=12’344) 
Group C 
 
Never BB 
 
(n=6131) 
P between 
groups 
Class I 76.9 77.3 84.5 66.1 < 0.001 
Class II 16.1 17.7 12.7 20.2 < 0.001 
Class III 4.5 4.0 2.0 8.5 < 0.001 
Class IV 2.5 1.0 0.8 5.2 < 0.001 
Between BB groups P<0.001 
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Table 3 - Reperfusion Therapy 
 All ACS 
patients 
ACS patients with valid data on beta 
receptor blocking agents (BB) 
(N=26,159) 
 
(%)  
n=26,964 
Group A 
 
Previous and 
continued BB  
 
 
(n=6234) 
Group B 
 
  BB on       
admission 
 
 
(n=12,344) 
Group C 
 
Never BB 
 
 
 
(n=6131) 
P between 
groups 
No reperfusion 48.8 54.2 44.1 52.0 <0.001 
Thrombolysis 10.2 6.7 12.7 9.7 <0.001 
Primary PCI 41.0 39.1 43.2 38.3 <0.001 
Between BB groups P<0.001 
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Table 4 - Complications and outcome of ACS patients in the AMIS Plus Registry 
 
 All ACS 
patients 
ACS patients with valid data on beta 
receptor blocking agents (BB) 
(N=26,159) 
P 
(n/N (%))  
n=26,964 
Previous and 
continued BB 
(n=6234) 
BB on 
admission 
(n=12,344) 
Never BB 
 
(n=6131) 
 
Cardiogenic shock 1909/26603 
(7.2) 
227/6161 
(3.7) 
469/12200 
(3.8) 
832/6046 
(13.8) 
<0.001 
Re-Infarction 637/26540 
(2.4) 
156/6152 
(2.5) 
236/12185 
(1.9) 
170/6025 
(2.8) 
<0.001 
Cerebrovascular event 279/26349 
(1.1) 
56/6111 
(0.9) 
80/12071 
(0.7) 
90/5995 
(1.5) 
<0.001 
MACE 2430/26396 
(9.2) 
399/6113 
(6.5) 
613/12078 
(5.1) 
930/6015 
(15.5) 
<0.001 
In-hospital mortality 1890/26964 
(7.0) 
256/6234 
(4.1) 
394/12344 
(3.2) 
808/6131 
(13.2) 
<0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
17 
17 
 
 
 
 
 
 
 
Table 5 - Multivariate logistic regression for MACE 
 
 
 Odds ratio 95% CI p 
Previous and 
continued β-blocker 
therapy 
0.59 0.47-0.74 <0.001 
β-blocker therapy at 
admission 
0.66 0.55-0.83 <0.001 
Age (per year) 1.04 1.04-1.05 <0.001 
Gender 1.16 0.97-1.39 0.112 
STEMI 1.55 1.30-1.86 <0.001 
Killip    
II 1.67 1.35-2.07 <0.001 
III 2.50 1.82-3.44 <0.001 
IV 15.6 11.3-21.7 <0.001 
Hypertension 0.84 0.70-1.01 0.069 
Dyslipidemia 0.79 0.67-0.94 0.009 
Smoking 1.22 1.00-1.50 0.055 
Charlson Score 1 1.42 1.13-1.79 0.003 
Charlson Score 2 1.72 1.32-2.24 <0.001 
Charlson Score ≥ 3 2.21 1.73-2.83 <0.001 
Primary PCI 0.59 0.49-0.72 <0.001 
 
 
 
